News concerning cell and gene therapy (CGT) may make you feel like you are on a rollercoaster. The ride moves very quickly with a lot of ups and downs, plus a few unexpected turns. As we move through 2023, excitement for CGT remains high, but there are lingering concerns about manufacturing and the ability of health care systems to keep up with the science.
I must admit, I’m a sucker for just about any list article. Show me a title such as, “8 Reasons Why…” or “10 Movies That…”, and there’s a pretty good chance I’ll click. I often find myself scrolling through the strangest lists, reviewing things that I really don’t care about – kitchen gadgets, closet organizing products, stocking stuffers. I’m hopeless. I’m compelled to click.
In cell and gene therapies, delivery is a critical factor. Regardless of your modality, optimizing payload, impact, and duration are common challenges. Countless programs, globally, are working on the delivery mechanism. However, many have overlooked a key component in improving therapeutic or manufacturing performance: the plasmid.
Insider Insights Inspire Ideas
I’ve spent most of the last 30 years in marketing and sales for molecular biology research products. During that time, I’ve been responsible for software platforms and instrumentation, but my main focus has been on reagents and consumables – nucleic acid purification, PCR, cloning tools, and so forth.
